Acute pancreatitis
1. Whitcomb DC. Clinical practice. Acute pancreatitis. N. Engl. J. Med. 2006;354(20):2142-2150. Available at: http://www.ncbi.nlm.nih.gov/pubmed/16707751 [Accessed January 9, 2010].
2. Gullo L. Day-to-day variations of serum pancreatic enzymes in benign pancreatic hyperenzymemia. Clin. Gastroenterol. Hepatol. 2007;5(1):70-74. Available at: http://www.ncbi.nlm.nih.gov/pubmed/17142107 [Accessed October 6, 2009].
Barrett’s esophagus
1. Corley DA, Kubo A, Levin TR, et al. Abdominal obesity and body mass index as risk factors for Barrett’s esophagus. Gastroenterology. 2007;133(1):34-41; quiz 311. Available at: http://www.ncbi.nlm.nih.gov/pubmed/17631128 [Accessed January 9, 2010].
2. Hirota WK, Zuckerman MJ, Adler DG, et al. ASGE guideline: the role of endoscopy in the surveillance of premalignant conditions of the upper GI tract. Gastrointest. Endosc. 2006;63(4):570-580. Available at: http://www.ncbi.nlm.nih.gov/pubmed/16564854 [Accessed January 9, 2010].
3. Corley DA, Kubo A, Levin TR, et al. Helicobacter pylori infection and the risk of Barrett’s oesophagus: a community-based study. Gut. 2008;57(6):727-733. Available at: http://www.ncbi.nlm.nih.gov/pubmed/17895354 [Accessed January 9, 2010].
4. Shaheen NJ, Sharma P, Overholt BF, et al. Radiofrequency ablation in Barrett’s esophagus with dysplasia. N. Engl. J. Med. 2009;360(22):2277-2288. Available at: http://www.ncbi.nlm.nih.gov/pubmed/19474425 [Accessed January 9, 2010].
5. Wang KK, Sampliner RE. Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett’s esophagus. Am. J. Gastroenterol. 2008;103(3):788-797. Available at: http://www.ncbi.nlm.nih.gov/pubmed/18341497 [Accessed January 9, 2010].
Celiac Sprue
1. Farrell RJ, Kelly CP. Celiac sprue. N. Engl. J. Med. 2002;346(3):180-188. Available at: http://www.ncbi.nlm.nih.gov/pubmed/11796853 [Accessed January 9, 2010].
2. Spiegel BMR, DeRosa VP, Gralnek IM, Wang V, Dulai GS. Testing for celiac sprue in irritable bowel syndrome with predominant diarrhea: a cost-effectiveness analysis. Gastroenterology. 2004;126(7):1721-1732. Available at: http://www.ncbi.nlm.nih.gov/pubmed/15188167 [Accessed January 9, 2010].
3. Ford AC, Chey WD, Talley NJ, et al. Yield of diagnostic tests for celiac disease in individuals with symptoms suggestive of irritable bowel syndrome: systematic review and meta-analysis. Arch. Intern. Med. 2009;169(7):651-658. Available at: http://www.ncbi.nlm.nih.gov/pubmed/19364994 [Accessed January 9, 2010].
Chronic diarrhea and C. diff
1. Zar FA, Bakkanagari SR, Moorthi KMLST, Davis MB. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin. Infect. Dis. 2007;45(3):302-307. Available at: http://www.ncbi.nlm.nih.gov/pubmed/17599306 [Accessed January 9, 2010].
2. Fine KD, Schiller LR. AGA technical review on the evaluation and management of chronic diarrhea. Gastroenterology. 1999;116(6):1464-1486. Available at: http://www.ncbi.nlm.nih.gov/pubmed/10348832 [Accessed January 9, 2010].
3. Hogenauer C, Langner C, Beubler E, et al. Klebsiella oxytoca as a Causative Organism of Antibiotic-Associated Hemorrhagic Colitis. N Engl J Med. 2006;355(23):2418-2426. Available at: http://content.nejm.org/cgi/content/abstract/355/23/2418 [Accessed October 6, 2009].
Chronic pancreatitis
1. Steer ML, Waxman I, Freedman S. Chronic pancreatitis. N. Engl. J. Med. 1995;332(22):1482-1490. Available at: http://www.ncbi.nlm.nih.gov/pubmed/7739686 [Accessed January 9, 2010].
2. Winstead NS, Wilcox CM. Clinical trials of pancreatic enzyme replacement for painful chronic pancreatitis–a review. Pancreatology. 2009;9(4):344-350. Available at: http://www.ncbi.nlm.nih.gov/pubmed/19451744 [Accessed January 9, 2010].
3. Shafiq N, Rana S, Bhasin D, et al. Pancreatic enzymes for chronic pancreatitis. Cochrane Database Syst Rev. 2009;(4):CD006302. Available at: http://www.ncbi.nlm.nih.gov/pubmed/19821359 [Accessed January 9, 2010].
Diverticular disease
1. Stollman NH, Raskin JB. Diagnosis and management of diverticular disease of the colon in adults. Ad Hoc Practice Parameters Committee of the American College of Gastroenterology. Am. J. Gastroenterol. 1999;94(11):3110-3121. Available at: http://www.ncbi.nlm.nih.gov/pubmed/10566700 [Accessed January 9, 2010].
2. Sheth AA, Longo W, Floch MH. Diverticular disease and diverticulitis. Am. J. Gastroenterol. 2008;103(6):1550-1556. Available at: http://www.ncbi.nlm.nih.gov/pubmed/18479497 [Accessed January 9, 2010].
Dyspepsia
1. Talley NJ, Vakil N. Guidelines for the management of dyspepsia. Am. J. Gastroenterol. 2005;100(10):2324-2337. Available at: http://www.ncbi.nlm.nih.gov/pubmed/16181387 [Accessed January 8, 2010].
Dysphagia
1. Lavu K, Mathew TP, Minocha A. Effectiveness of esophageal dilation in relieving nonobstructive esophageal dysphagia and improving quality of life. South. Med. J. 2004;97(2):137-140. Available at: http://www.ncbi.nlm.nih.gov/pubmed/14982261 [Accessed January 8, 2010].
2. Arora AS, Yamazaki K. Eosinophilic esophagitis: asthma of the esophagus? Clin. Gastroenterol. Hepatol. 2004;2(7):523-530. Available at: http://www.ncbi.nlm.nih.gov/pubmed/15224275 [Accessed January 8, 2010].
3. Schoepfer AM, Gonsalves N, Bussmann C, et al. Esophageal Dilation in Eosinophilic Esophagitis: Effectiveness, Safety, and Impact on the Underlying Inflammation. Am. J. Gastroenterol. 2009. Available at: http://www.ncbi.nlm.nih.gov/pubmed/19935783 [Accessed January 8, 2010].
4. Aceves SS, Bastian JF, Newbury RO, Dohil R. Oral viscous budesonide: a potential new therapy for eosinophilic esophagitis in children. Am. J. Gastroenterol. 2007;102(10):2271-2279; quiz 2280. Available at: http://www.ncbi.nlm.nih.gov/pubmed/17581266 [Accessed January 8, 2010].
5. Colon VJ, Young MA, Ramirez FC. The short- and long-term efficacy of empirical esophageal dilation in patients with nonobstructive dysphagia: a prospective, randomized study. Am. J. Gastroenterol. 2000;95(4):910-913. Available at: http://www.ncbi.nlm.nih.gov/pubmed/10763936 [Accessed January 8, 2010].
General gastroenterology
1. Wexner SD, Beck DE, Baron TH, et al. A consensus document on bowel preparation before colonoscopy: prepared by a task force from the American Society of Colon and Rectal Surgeons (ASCRS), the American Society for Gastrointestinal Endoscopy (ASGE), and the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES). Gastrointest. Endosc. 2006;63(7):894-909. Available at: http://www.ncbi.nlm.nih.gov/pubmed/16733101 [Accessed January 9, 2010].
2. Qureshi WA, Rajan E, Adler DG, et al. ASGE Guideline: Guidelines for endoscopy in pregnant and lactating women. Gastrointest. Endosc. 2005;61(3):357-362. Available at: http://www.ncbi.nlm.nih.gov/pubmed/15758903 [Accessed January 9, 2010].
3. Zuckerman MJ, Hirota WK, Adler DG, et al. ASGE guideline: the management of low-molecular-weight heparin and nonaspirin antiplatelet agents for endoscopic procedures. Gastrointest. Endosc. 2005;61(2):189-194. Available at: http://www.ncbi.nlm.nih.gov/pubmed/15729224 [Accessed January 9, 2010].
4. Cummings JE, Schweikert RA, Saliba WI, et al. Brief communication: atrial-esophageal fistulas after radiofrequency ablation. Ann. Intern. Med. 2006;144(8):572-574. Available at: http://www.ncbi.nlm.nih.gov/pubmed/16618954 [Accessed October 6, 2009].
5. Srinivasan R, Greenbaum DS. Chronic abdominal wall pain: a frequently overlooked problem. Practical approach to diagnosis and management. Am. J. Gastroenterol. 2002;97(4):824-830. Available at: http://www.ncbi.nlm.nih.gov/pubmed/12003414 [Accessed January 9, 2010].
6. Kim DH, Pickhardt PJ, Taylor AJ, et al. CT colonography versus colonoscopy for the detection of advanced neoplasia. N. Engl. J. Med. 2007;357(14):1403-1412. Available at: http://www.ncbi.nlm.nih.gov/pubmed/17914041 [Accessed January 9, 2010].
7. Petersen BT, Hussain N, Marine JE, et al. Endoscopy in patients with implanted electronic devices. Gastrointest. Endosc. 2007;65(4):561-568. Available at: http://www.ncbi.nlm.nih.gov/pubmed/17383453 [Accessed January 9, 2010].
8. Guideline on the management of anticoagulation and antiplatelet therapy for endoscopic procedures. Available at: http://www.asge.org/WorkArea/showcontent.aspx?id=7142 [Accessed January 9, 2010].
9. Rex DK, Kahi CJ, Levin B, et al. Guidelines for colonoscopy surveillance after cancer resection: a consensus update by the American Cancer Society and the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology. 2006;130(6):1865-1871. Available at: http://www.ncbi.nlm.nih.gov/pubmed/16697749 [Accessed October 6, 2009].
10. Winawer SJ, Zauber AG, Fletcher RH, et al. Guidelines for colonoscopy surveillance after polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer and the American Cancer Society. Gastroenterology. 2006;130(6):1872-1885. Available at: http://www.ncbi.nlm.nih.gov/pubmed/16697750 [Accessed October 6, 2009].
11. Occhipinti KE, Di Palma JA. How to choose the best preparation for colonoscopy. Nat Rev Gastroenterol Hepatol. 2009;6(5):279-286. Available at: http://www.ncbi.nlm.nih.gov/pubmed/19404268 [Accessed January 9, 2010].
12. Talley NJ. How to do and interpret a rectal examination in gastroenterology. Am. J. Gastroenterol. 2008;103(4):820-822. Available at: http://www.ncbi.nlm.nih.gov/pubmed/18397419 [Accessed October 6, 2009].
13. Gulmez SE, Holm A, Frederiksen H, et al. Use of proton pump inhibitors and the risk of community-acquired pneumonia: a population-based case-control study. Arch. Intern. Med. 2007;167(9):950-955. Available at: http://www.ncbi.nlm.nih.gov/pubmed/17502537 [Accessed January 9, 2010].
GERD
1. Frye JW, Vaezi MF. Extraesophageal GERD. Gastroenterol Clin North Am. 2008;37(4):845-58, ix. Available at: http://www.ncbi.nlm.nih.gov/pubmed/19028321 [Accessed March 25, 2009].
2. Kahrilas PJ. Gastroesophageal reflux disease. JAMA. 1996;276(12):983-988. Available at: http://www.ncbi.nlm.nih.gov/pubmed/8805734 [Accessed January 8, 2010].
3. Richter JE. How to manage refractory GERD. Nat Clin Pract Gastroenterol Hepatol. 2007;4(12):658-664. Available at: http://www.ncbi.nlm.nih.gov/pubmed/18043675 [Accessed January 8, 2010].
IBD
1. Akram S, Murray JA, Pardi DS, et al. Adult autoimmune enteropathy: Mayo Clinic Rochester experience. Clin. Gastroenterol. Hepatol. 2007;5(11):1282-1290; quiz 1245. Available at: http://www.ncbi.nlm.nih.gov/pubmed/17683994 [Accessed October 6, 2009].
2. Gearry RB, Barclay ML. Azathioprine and 6-mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel disease. J. Gastroenterol. Hepatol. 2005;20(8):1149-1157. Available at: http://www.ncbi.nlm.nih.gov/pubmed/16048561 [Accessed January 8, 2010].
3. Ahmadi AA, Polyak S. Endoscopy/surveillance in inflammatory bowel disease. Surg. Clin. North Am. 2007;87(3):743-762. Available at: http://www.ncbi.nlm.nih.gov/pubmed/17560423 [Accessed January 8, 2010].
4. Sandborn WJ, Hanauer SB. Infliximab in the treatment of Crohn’s disease: a user’s guide for clinicians. Am. J. Gastroenterol. 2002;97(12):2962-2972. Available at: http://www.ncbi.nlm.nih.gov/pubmed/12492177 [Accessed January 8, 2010].
5. Beaugerie L, Brousse N, Bouvier AM, et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. The Lancet. 2009;374(9701):1617-1625. Available at: http://www.thelancet.com/journals/lancet/article/PIIS0140673609613027/abstract?_eventId=login&rss=yes [Accessed December 17, 2009].
6. Lichtenstein GR, Hanauer SB, Sandborn WJ. Management of Crohn’s disease in adults. Am. J. Gastroenterol. 2009;104(2):465-483; quiz 464, 484. Available at: http://www.ncbi.nlm.nih.gov/pubmed/19174807 [Accessed January 8, 2010].
7. Terdiman JP. Prevention of postoperative recurrence in Crohn’s disease. Clin. Gastroenterol. Hepatol. 2008;6(6):616-620. Available at: http://www.ncbi.nlm.nih.gov/pubmed/17967564 [Accessed January 8, 2010].
8. Waljee A, Waljee J, Morris AM, Higgins PDR. Threefold increased risk of infertility: a meta-analysis of infertility after ileal pouch anal anastomosis in ulcerative colitis. Gut. 2006;55(11):1575-1580. Available at: http://www.ncbi.nlm.nih.gov/pubmed/16772310 [Accessed January 8, 2010].
9. Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology, Practice Parameters Committee. Am. J. Gastroenterol. 2004;99(7):1371-1385. Available at: http://www.ncbi.nlm.nih.gov/pubmed/15233681 [Accessed January 8, 2010].
10. Francis G, Duggan A. Withdrawal of Immunosuppression in Crohn’s Disease Treated With Scheduled Infliximab Maintenance. Gastroenterology. 2008;135(6):2156-2157. Available at: http://www.gastrojournal.org/PhoenixWeb/PhoenixServlet/article/S0016-5085(08)01854-4/abstract [Accessed October 6, 2009].
IBS
1. Drossman DA, Camilleri M, Mayer EA, Whitehead WE. AGA technical review on irritable bowel syndrome. Gastroenterology. 2002;123(6):2108-2131. Available at: http://www.ncbi.nlm.nih.gov/pubmed/12454866 [Accessed January 8, 2010].
2. Brandt LJ, Chey WD, Foxx-Orenstein AE, et al. An evidence-based position statement on the management of irritable bowel syndrome. Am. J. Gastroenterol. 2009;104 Suppl 1:S1-35. Available at: http://www.ncbi.nlm.nih.gov/pubmed/19521341 [Accessed January 8, 2010].
3. Camilleri M. Management of the irritable bowel syndrome. Gastroenterology. 2001;120(3):652-668. Available at: http://www.ncbi.nlm.nih.gov/pubmed/11179242 [Accessed January 8, 2010].
4. Houghton LA, Whorwell PJ. Towards a better understanding of abdominal bloating and distension in functional gastrointestinal disorders. Neurogastroenterol. Motil. 2005;17(4):500-511. Available at: http://www.ncbi.nlm.nih.gov/pubmed/16078938 [Accessed January 8, 2010].
Ischemic colitis
1. Brandt LJ, Boley SJ. AGA technical review on intestinal ischemia. American Gastrointestinal Association. Gastroenterology. 2000;118(5):954-968. Available at: http://www.ncbi.nlm.nih.gov/pubmed/10784596 [Accessed January 9, 2010].
Liver transplant
1. Yao FY, Ferrell L, Bass NM, et al. Liver transplantation for hepatocellular carcinoma: comparison of the proposed UCSF criteria with the Milan criteria and the Pittsburgh modified TNM criteria. Liver Transpl. 2002;8(9):765-774. Available at: http://www.ncbi.nlm.nih.gov/pubmed/12200775 [Accessed January 9, 2010].
2. Londoño M, Cárdenas A, Guevara M, et al. MELD score and serum sodium in the prediction of survival of patients with cirrhosis awaiting liver transplantation. Gut. 2007;56(9):1283-1290. Available at: http://www.ncbi.nlm.nih.gov/pubmed/17452425 [Accessed December 17, 2009].
3. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 2008;359(4):378-390. Available at: http://www.ncbi.nlm.nih.gov/pubmed/18650514 [Accessed January 9, 2010].
Lower GI bleeding
1. Wilcox CM, Alexander LN, Cotsonis G. A prospective characterization of upper gastrointestinal hemorrhage presenting with hematochezia. Am. J. Gastroenterol. 1997;92(2):231-235. Available at: http://www.ncbi.nlm.nih.gov/pubmed/9040197 [Accessed January 8, 2010].
2. Jensen DM, Machicado GA. Diagnosis and treatment of severe hematochezia. The role of urgent colonoscopy after purge. Gastroenterology. 1988;95(6):1569-1574. Available at: http://www.ncbi.nlm.nih.gov/pubmed/3263294 [Accessed January 8, 2010].
3. Zuccaro G. Management of the adult patient with acute lower gastrointestinal bleeding. American College of Gastroenterology. Practice Parameters Committee. Am. J. Gastroenterol. 1998;93(8):1202-1208. Available at: http://www.ncbi.nlm.nih.gov/pubmed/9707037 [Accessed January 8, 2010].
4. Strate LL, Ayanian JZ, Kotler G, Syngal S. Risk factors for mortality in lower intestinal bleeding. Clin. Gastroenterol. Hepatol. 2008;6(9):1004-1010; quiz 955-. Available at: http://www.ncbi.nlm.nih.gov/pubmed/18558513 [Accessed January 8, 2010].
NSAID toxicity
1. Taha AS, McCloskey C, Prasad R, Bezlyak V. Famotidine for the prevention of peptic ulcers and oesophagitis in patients taking low-dose aspirin (FAMOUS): a phase III, randomised, double-blind, placebo-controlled trial. Lancet. 2009;374(9684):119-125. Available at: http://www.ncbi.nlm.nih.gov/pubmed/19577798 [Accessed October 6, 2009].
2. Van Os EC, Kamath PS, Gostout CJ, Heit JA. Gastroenterological procedures among patients with disorders of hemostasis: evaluation and management recommendations. Gastrointest. Endosc. 1999;50(4):536-543. Available at: http://www.ncbi.nlm.nih.gov/pubmed/10502177 [Accessed January 8, 2010].
3. Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N. Engl. J. Med. 1999;340(24):1888-1899. Available at: http://www.ncbi.nlm.nih.gov/pubmed/10369853 [Accessed January 8, 2010].
4. Devlin JW, Welage LS, Olsen KM. Proton pump inhibitor formulary considerations in the acutely ill. Part 1: Pharmacology, pharmacodynamics, and available formulations. Ann Pharmacother. 2005;39(10):1667-1677. Available at: http://www.ncbi.nlm.nih.gov/pubmed/16118266 [Accessed January 8, 2010].
5. Devlin JW, Welage LS, Olsen KM. Proton pump inhibitor formulary considerations in the acutely ill. Part 2: Clinical efficacy, safety, and economics. Ann Pharmacother. 2005;39(11):1844-1851. Available at: http://www.ncbi.nlm.nih.gov/pubmed/16204393 [Accessed January 8, 2010].
6. Ray WA, Chung CP, Stein CM, et al. Risk of peptic ulcer hospitalizations in users of NSAIDs with gastroprotective cotherapy versus coxibs. Gastroenterology. 2007;133(3):790-798. Available at: http://www.ncbi.nlm.nih.gov/pubmed/17854591 [Accessed January 8, 2010].
Occult gastrointestinal bleeding
1. Rockey DC, Auslander A, Greenberg PD. Detection of upper gastrointestinal blood with fecal occult blood tests. Am. J. Gastroenterol. 1999;94(2):344-350. Available at: http://www.ncbi.nlm.nih.gov/pubmed/10022627 [Accessed January 8, 2010].
2. Rockey DC. Occult gastrointestinal bleeding. N. Engl. J. Med. 1999;341(1):38-46. Available at: http://www.ncbi.nlm.nih.gov/pubmed/10387941 [Accessed January 8, 2010].
Other liver disease:
1. Roberts EA, Schilsky ML. Diagnosis and treatment of Wilson disease: an update. Hepatology. 2008;47(6):2089-2111. Available at: http://www.ncbi.nlm.nih.gov/pubmed/18506894 [Accessed January 9, 2010].
2. Bacon BR. Hemochromatosis: diagnosis and management. Gastroenterology. 2001;120(3):718-725. Available at: http://www.ncbi.nlm.nih.gov/pubmed/11179246 [Accessed January 9, 2010].
3. Teh SH, Nagorney DM, Stevens SR, et al. Risk factors for mortality after surgery in patients with cirrhosis. Gastroenterology. 2007;132(4):1261-1269. Available at: http://www.ncbi.nlm.nih.gov/pubmed/17408652 [Accessed December 17, 2009].
Upper GI bleeding and ulcers
1. Schmulewitz N, Baillie J. Dieulafoy lesions: a review of 6 years of experience at a tertiary referral center. Am. J. Gastroenterol. 2001;96(6):1688-1694. Available at: http://www.ncbi.nlm.nih.gov/pubmed/11419815 [Accessed January 8, 2010].
2. Bini EJ, Cohen J. Endoscopic treatment compared with medical therapy for the prevention of recurrent ulcer hemorrhage in patients with adherent clots. Gastrointest. Endosc. 2003;58(5):707-714. Available at: http://www.ncbi.nlm.nih.gov/pubmed/14595306 [Accessed January 8, 2010].
3. Winstead NS, Wilcox CM. Erythromycin prior to endoscopy for acute upper gastrointestinal haemorrhage: a cost-effectiveness analysis. Aliment. Pharmacol. Ther. 2007;26(10):1371-1377. Available at: http://www.ncbi.nlm.nih.gov/pubmed/17848180 [Accessed January 8, 2010].
4. Carmack SW, Genta RM, Graham DY, Lauwers GY. Management of gastric polyps: a pathology-based guide for gastroenterologists. Nat Rev Gastroenterol Hepatol. 2009;6(6):331-341. Available at: http://www.ncbi.nlm.nih.gov/pubmed/19421245 [Accessed January 8, 2010].
5. Jensen D. Randomized trial of medical or endoscopic therapy to prevent recurrent ulcer hemorrhage in patients with adherent clots. Gastroenterology. 2002;123(2):407-413. Available at: http://www.gastrojournal.org/article/S0016-5085(02)00118-X/abstract [Accessed October 6, 2009].
6. Saini SD, Eisen G, Mattek N, Schoenfeld P. Utilization of upper endoscopy for surveillance of gastric ulcers in the United States. Am. J. Gastroenterol. 2008;103(8):1920-1925. Available at: http://www.ncbi.nlm.nih.gov/pubmed/18796092 [Accessed January 8, 2010].
Viral hepatitis
1. Perrillo RP. Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease. Gastroenterology. 2001;120(4):1009-1022. Available at: http://www.ncbi.nlm.nih.gov/pubmed/11231956 [Accessed January 9, 2010].
2. Lok ASF, McMahon BJ. Chronic hepatitis B. Hepatology. 2007;45(2):507-539. Available at: http://www.ncbi.nlm.nih.gov/pubmed/17256718 [Accessed January 9, 2010].
3. Fung SK, Fontana RJ. Management of drug-resistant chronic hepatitis B. Clin Liver Dis. 2006;10(2):275-302, viii. Available at: http://www.ncbi.nlm.nih.gov/pubmed/16971262 [Accessed January 9, 2010].
4. National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C 2002 (June 10-12, 2002). Gastroenterology. 2002;123(6):2082-2099. Available at: http://www.ncbi.nlm.nih.gov/pubmed/12454863 [Accessed January 9, 2010].
5. Lok AS. Navigating the maze of hepatitis B treatments. Gastroenterology. 2007;132(4):1586-1594. Available at: http://www.ncbi.nlm.nih.gov/pubmed/17408643 [Accessed January 9, 2010].
6. Shiffman ML, Suter F, Bacon BR, et al. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N. Engl. J. Med. 2007;357(2):124-134. Available at: http://www.ncbi.nlm.nih.gov/pubmed/17625124 [Accessed January 9, 2010].
7. Zeuzem S, Feinman SV, Rasenack J, et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N. Engl. J. Med. 2000;343(23):1666-1672. Available at: http://www.ncbi.nlm.nih.gov/pubmed/11106715 [Accessed January 9, 2010].
8. Tillmann HL, Hadem J, Leifeld L, et al. Safety and efficacy of lamivudine in patients with severe acute or fulminant hepatitis B, a multicenter experience. J. Viral Hepat. 2006;13(4):256-263. Available at: http://www.ncbi.nlm.nih.gov/pubmed/16611192 [Accessed October 6, 2009].
9. Hézode C, Forestier N, Dusheiko G, et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N. Engl. J. Med. 2009;360(18):1839-1850. Available at: http://www.ncbi.nlm.nih.gov/pubmed/19403903 [Accessed January 9, 2010].
10. McHutchison JG, Everson GT, Gordon SC, et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N. Engl. J. Med. 2009;360(18):1827-1838. Available at: http://www.ncbi.nlm.nih.gov/pubmed/19403902 [Accessed January 9, 2010].